

USTEKINUMAB solution for injection (Stelara®) for ulcerative colitis

The Pan Mersey Area Prescribing Committee recommends the prescribing of USTEKINUMAB solution for injection (Stelara®), by specialists only, for moderately to severely active ulcerative colitis in accordance with NICE TA633.

RED

NICE technology appraisal [TA633](#) (17 June 2020) recommends ustekinumab as an option for treating moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if:

- > a tumour necrosis factor-alpha inhibitor has failed (that is the disease has responded inadequately or has lost response to treatment) or
- > a tumour necrosis factor-alpha inhibitor cannot be tolerated or is not suitable; and
- > the company provides ustekinumab at the same price or lower than that agreed with the Commercial Medicines Unit.^[1]

Prescribing and monitoring of therapy must be retained by a specialist in the management of ulcerative colitis.

NICE do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations will be less than £5 million per year in England (or £9,000 per 100,000 population).^[2]

References

1. National Institute for Health and Care Excellence. Technology Appraisal 633: [Ustekinumab for treating moderately to severely active ulcerative colitis](#), 17 June 2020. Accessed 17 June 2020.
2. National Institute for Health and Care Excellence. Technology Appraisal 633: [Resource impact statement](#), 17 June 2020. Accessed 17 June 2020.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.